KDM2B

Across TCGA pan-cancer cohorts, KDM2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KDM2B data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KDM2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KDM2B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where KDM2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.311	0.612	<.001	32	view →
LSCC	DFS	Median	All	0.823	0.615	.009	15	view →
HNSC	OS	Median	All	0.800	0.889	.021	7	view →
LUAD	OS	Tertile	II,III,IV	0.879	0.585	.041	3	view →
GBM	DFS	Tertile	All	0.614	0.833	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KDM2B–PDAC (OS)

Open the PDAC breakdown →